Javascript must be enabled to continue!
Psychological aspects of patients with Fabry disease
View through CrossRef
SummaryThe Minnesota Muliphasic Personality Inventory (MMPI‐2) is widely used in chronic illness and chronic pain populations to assess psychological functioning. We report the results of the first investigation using the MMPI‐2 to assess psychological aspects of patients with Fabry disease. Fabry disease, an X‐linked lysosomal storage disorder, is a multisystem progressive disease affecting the kidney, heart, and central nervous system, and is particularly associated with chronic symptoms including pain. In this study, 28 patients with Fabry disease completed the MMPI‐2 and a background questionnaire. Fabry disease patients scored significantly higher than the MMPI‐2 normative sample on seven clinical scales (Hs, D, Hy, Pd, Pa, Pt, Sc) and two validity scales (L, F). Individuals with elevated scores on the Hs, D, and Hy scales tend to have somatic complaints, sadness, and emotional distress. Under stress, they may experience an increase in physical symptoms. Elevated Pd, Pa, Pt, and Sc scales suggest social maladjustment, suspiciousness, and feelings of isolation. An elevated L scale suggests defensiveness; a high score on F suggests emotional turmoil. When compared with cohorts of patients with Gaucher disease (GD), chronic heart disease (CRHD), and chronic pain, the Fabry disease patients had significantly higher scores than GD patients and CRHD patients on numerous clinical (Hs, D, Si), and validity (F) scales underscoring the relative amount of suffering and pain experienced by Fabry disease patients. No significant differences on any MMPI‐2 scales were found between the Fabry disease patients and the pain patients, suggesting that Fabry disease patients may be comparable to pain patient populations.
Title: Psychological aspects of patients with Fabry disease
Description:
SummaryThe Minnesota Muliphasic Personality Inventory (MMPI‐2) is widely used in chronic illness and chronic pain populations to assess psychological functioning.
We report the results of the first investigation using the MMPI‐2 to assess psychological aspects of patients with Fabry disease.
Fabry disease, an X‐linked lysosomal storage disorder, is a multisystem progressive disease affecting the kidney, heart, and central nervous system, and is particularly associated with chronic symptoms including pain.
In this study, 28 patients with Fabry disease completed the MMPI‐2 and a background questionnaire.
Fabry disease patients scored significantly higher than the MMPI‐2 normative sample on seven clinical scales (Hs, D, Hy, Pd, Pa, Pt, Sc) and two validity scales (L, F).
Individuals with elevated scores on the Hs, D, and Hy scales tend to have somatic complaints, sadness, and emotional distress.
Under stress, they may experience an increase in physical symptoms.
Elevated Pd, Pa, Pt, and Sc scales suggest social maladjustment, suspiciousness, and feelings of isolation.
An elevated L scale suggests defensiveness; a high score on F suggests emotional turmoil.
When compared with cohorts of patients with Gaucher disease (GD), chronic heart disease (CRHD), and chronic pain, the Fabry disease patients had significantly higher scores than GD patients and CRHD patients on numerous clinical (Hs, D, Si), and validity (F) scales underscoring the relative amount of suffering and pain experienced by Fabry disease patients.
No significant differences on any MMPI‐2 scales were found between the Fabry disease patients and the pain patients, suggesting that Fabry disease patients may be comparable to pain patient populations.
Related Results
#2343 Fabry disease screening in patients with chronic kidney disease and dialysis at a single medical center in Taiwan
#2343 Fabry disease screening in patients with chronic kidney disease and dialysis at a single medical center in Taiwan
Abstract
Background and Aims
Chronic Kidney Disease (CKD) poses a significant global health challenge, with diverse contributing...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Cornea verticillata in Fabry disease
Cornea verticillata in Fabry disease
Cornea verticillata is the typical sign of ocular involvement in Fabry disease and manifests by the whorl-like, linear opacities in the inferior part of the cornea. Aim. To study t...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Cardiac manifestations of fabry disease in female patients: a single centre experience
Cardiac manifestations of fabry disease in female patients: a single centre experience
Abstract
Introduction
Fabry disease is a lysosomal storage disorder resulting in multisystemic effects due to deposition and acc...
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
AbstractBackground Fabry disease is a rare X‐linked disorder caused by deficient activity of the lysosomal enzyme α‐galactosidase A. Progressive accumulation of the substrate glob...
Biomarkers for Diagnosing and Staging of Fabry Disease
Biomarkers for Diagnosing and Staging of Fabry Disease
Background:
Fabry disease is an X-linked lysosomal storage disorder caused by
deficient activity of α -galactosidase A which leads to progressive intracellular accumulation
of glo...
Investigating Fabry disease - some lessons learned
Investigating Fabry disease - some lessons learned
Despite recent advances, there is still much to be learned about the pathogenesis of Fabry disease. The categorization of GLA gene missense mutations has been complicated by the f...

